Braintropia

Braintropia is a French biotechnology company dedicated to developing first-in-class neuroprotective therapies for neurodegenerative disorders, with a primary focus on Parkinson's disease. The company utilizes a unique metabolic reprogramming approach to restore mitochondrial function and energy homeostasis in neurons, aiming to halt disease progression. Founded as a spin-off from Inserm and the University of Strasbourg, Braintropia leverages deep expertise in the metabolic pathways that underlie neuronal health. Its lead small molecule candidates are designed to provide disease-modifying effects by addressing the root causes of cellular failure rather than merely managing symptoms.